Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
8871 | 1141 | 51.9 | 94% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
532 | 14062 | TOLL LIKE RECEPTOR//TOLL LIKE RECEPTORS//CD14 |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | UNC93B1 | Author keyword | 11 | 78% | 1% | 7 |
2 | MARY KIRKLAND LUPUS | Address | 9 | 43% | 1% | 16 |
3 | TLR7 | Author keyword | 9 | 25% | 3% | 31 |
4 | TOLL LIKE RECEPTOR 7 | Author keyword | 7 | 29% | 2% | 20 |
5 | AUTOIMMUN MUSCULOSKELETAL DIS | Address | 4 | 47% | 1% | 7 |
6 | TLR 7 | Author keyword | 3 | 43% | 1% | 6 |
7 | GWEN KN P LUPUS | Address | 3 | 60% | 0% | 3 |
8 | RUSH LUPUS CLIN | Address | 3 | 60% | 0% | 3 |
9 | TLR7 AGONIST | Author keyword | 3 | 60% | 0% | 3 |
10 | GWEN KN P LUPUS IMMUNOL | Address | 3 | 13% | 2% | 19 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | UNC93B1 | 11 | 78% | 1% | 7 | Search UNC93B1 | Search UNC93B1 |
2 | TLR7 | 9 | 25% | 3% | 31 | Search TLR7 | Search TLR7 |
3 | TOLL LIKE RECEPTOR 7 | 7 | 29% | 2% | 20 | Search TOLL+LIKE+RECEPTOR+7 | Search TOLL+LIKE+RECEPTOR+7 |
4 | TLR 7 | 3 | 43% | 1% | 6 | Search TLR+7 | Search TLR+7 |
5 | TLR7 AGONIST | 3 | 60% | 0% | 3 | Search TLR7+AGONIST | Search TLR7+AGONIST |
6 | TOLL LIKE RECEPTOR 8 | 2 | 32% | 1% | 6 | Search TOLL+LIKE+RECEPTOR+8 | Search TOLL+LIKE+RECEPTOR+8 |
7 | GARDIQUIMOD | 2 | 67% | 0% | 2 | Search GARDIQUIMOD | Search GARDIQUIMOD |
8 | SIFALIMUMAB | 2 | 67% | 0% | 2 | Search SIFALIMUMAB | Search SIFALIMUMAB |
9 | IMIDAZOQUINOLINE | 2 | 24% | 1% | 7 | Search IMIDAZOQUINOLINE | Search IMIDAZOQUINOLINE |
10 | ADENINE DERIVATIVES | 2 | 24% | 1% | 6 | Search ADENINE+DERIVATIVES | Search ADENINE+DERIVATIVES |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | ACTIVATE B CELLS | 45 | 51% | 5% | 62 |
2 | APOPTOTIC U937 CELLS | 29 | 75% | 2% | 21 |
3 | TOLL LIKE RECEPTOR 7 | 27 | 40% | 5% | 53 |
4 | TLR7 | 26 | 40% | 4% | 50 |
5 | I INTERFERON | 21 | 12% | 15% | 170 |
6 | ALPHA PRODUCING CELLS | 21 | 35% | 4% | 49 |
7 | IFN ALPHA | 20 | 12% | 14% | 159 |
8 | MURINE LUPUS | 16 | 11% | 12% | 137 |
9 | 8 HYDROXYADENINES | 15 | 82% | 1% | 9 |
10 | POTENT INTERFERON INDUCERS | 12 | 86% | 1% | 6 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
The interferon signature in autoimmune diseases | 2013 | 49 | 48 | 40% |
Type I Interferon in the Pathogenesis of Lupus | 2014 | 16 | 127 | 43% |
A cell biological view of Toll-like receptor function: regulation through compartmentalization | 2009 | 241 | 62 | 35% |
Intracellular Toll-like Receptors | 2010 | 306 | 110 | 24% |
Anti-interferon alpha treatment in SLE | 2013 | 22 | 71 | 62% |
Toll-like receptor driven B cell activation in the induction of systemic autoimmunity | 2011 | 67 | 94 | 49% |
Type I interferon blockade in systemic lupus erythematosus: where do we stand? | 2014 | 6 | 55 | 60% |
Trafficking of endosomal Toll-like receptors | 2014 | 7 | 97 | 54% |
Type I IFN system in the development and manifestations of SLE | 2012 | 39 | 46 | 46% |
Targeting of type I interferon in systemic autoimmune diseases | 2015 | 1 | 65 | 51% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | MARY KIRKLAND LUPUS | 9 | 43% | 1.4% | 16 |
2 | AUTOIMMUN MUSCULOSKELETAL DIS | 4 | 47% | 0.6% | 7 |
3 | GWEN KN P LUPUS | 3 | 60% | 0.3% | 3 |
4 | RUSH LUPUS CLIN | 3 | 60% | 0.3% | 3 |
5 | GWEN KN P LUPUS IMMUNOL | 3 | 13% | 1.7% | 19 |
6 | JR GRP TOLL RECEPTORS CANC | 2 | 67% | 0.2% | 2 |
7 | MED B31 | 2 | 67% | 0.2% | 2 |
8 | PFIZER OLIGONUCLEOTIDE THER EUT UNIT | 2 | 50% | 0.3% | 3 |
9 | INFECT DIS MED MICROBIOL HYG | 2 | 15% | 1.0% | 11 |
10 | SHANGHAI RHEUMATOL | 1 | 25% | 0.4% | 5 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000190145 | CPG ODN//CPG MOTIF//CPG DNA |
2 | 0.0000177748 | HANS WILSDORF//CLIN IMMUNOL UNITHANS WILSDORF//IMMUNOL ALLERGYCLIN IMMUNOL UNIT |
3 | 0.0000176490 | PLASMACYTOID DENDRITIC CELLS//BDCA 4//PLASMACYTOID DENDRITIC CELL |
4 | 0.0000171325 | RIG I//IRF3//MDA5 |
5 | 0.0000150108 | PTPN22//PROTEIN TYROSINE PHOSPHATASE NONRECEPTOR 22//IRF5 |
6 | 0.0000149354 | TIR DOMAIN//PELLINO//INNATE IMMUN INFLAMMAT |
7 | 0.0000127787 | IL10 GENE//INTERLEUKIN 10 PROMOTER//RHEUMATOL INTERNAL MED 3 |
8 | 0.0000118023 | INNATE IMMUNITY OF THE SKIN//PERMAFROST MICROORGANISMS//TYUMEN |
9 | 0.0000116566 | CD14//CD14 POLYMORPHISM//TLR4 POLYMORPHISM |
10 | 0.0000104490 | TOLL LIKE RECEPTOR 9//TOLL LIKE RECEPTOR 3//95D CELL |